Press Releases Year All News20192018201720162015 Forty Seven, Inc. Announces Updated Data from Phase 1b/2 Clinical Trial of 5F9 in Combination with Rituximab in Patients with Relapsed/Refractory Non-Hodgkin’s Lymphoma June 15, 2019 Forty Seven, Inc. Announces Updated Initial Data from Phase 1b Clinical Trial of 5F9 in Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia June 3, 2019 Forty Seven, Inc. to Present Updated Data from Ongoing Phase 1b/2 Clinical Trial of 5F9 in Patients with Relapsed/Refractory Non-Hodgkin’s Lymphoma at 24th Congress of the European Hematology Association May 16, 2019 Forty Seven, Inc. to Present Initial Safety and Efficacy Data from Phase 1b Clinical Trial of 5F9 in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome at 2019 ASCO Annual Meeting May 15, 2019 Forty Seven Inc. Reports First Quarter 2019 Financial Results and Recent Business Highlights May 13, 2019 Forty Seven Inc. and Acerta Enter Collaboration to Evaluate Novel Immuno-Oncology Triple Combination in Diffuse Large B-cell Lymphoma May 10, 2019 Forty Seven Inc. to Report First Quarter 2019 Financial Results on Monday, May 13, 2019 May 6, 2019 Forty Seven Inc. Expands Collaboration with Genentech to Include Third Clinical Trial in Non-Hodgkin’s Lymphoma April 26, 2019 Forty Seven Inc. Reports Fourth Quarter and Full Year 2018 Financial Results and Recent Business Highlights March 28, 2019 Forty Seven Inc. to Report Fourth Quarter and Full Year 2018 Financial Results on Thursday, March 28, 2019 March 21, 2019 Pagination Current page 1 Page 2 Next page next › Last page last » Displaying 1 - 10 of 14
